MRC CASE Studentship with AstraZenica
University of Liverpool
Exciting PhD Opportunity in Immuno-Oncology, Autoimmunity & Neuroscience in Dickens Lab
Are you ready to tackle one of the most pressing safety challenges in immuno-oncology? We are offering a fully funded MRC NW-DMS CASE PhD studentship in the Dickens Lab, in collaboration with AstraZeneca, where you will contribute to cutting edge research with real world impact.
This multidisciplinary project is a scientifically rigorous, translational project at the nexus of neuroscience, immunology, and drug safety. You will investigate Immune Cell-Associated Neurotoxicity Syndrome (ICANS)- an acute, potentially severe neurologic toxicity that can occur after T-cell–based therapies by decoding how blood–brain barrier (BBB) integrity is compromised and how we can protect it.
Multidisciplinary team with internationally recognised expertise:
David Dickens (BBB biology, University of Liverpool)
Munir Pirmohamed (Drug safety and clinical pharmacology, University of Liverpool)
Mahnoush Bahjat (Immunotoxicology, AstraZeneca)
Albena Dinkova-Kostova (NRF2 biology, University of Dundee)
The team has a strong track record in PhD mentorship and in developing innovative advanced cell based models to evaluate immune safety risks.
For further information please see https://www.findaphd.com/phds/project/mrc-nw-dms-dla-programme-towards-mitigating-severe-neurotoxicity-in-t-cell-immunotherapy/?p201561
All applications are made via the application form accessed on the NW-DMS website at https://www.liverpool.ac.uk/doctoral-training/mrc-nwdp/apply/ with the deadline for applications being the 27th of November 2026. Realistically this is a fully funded project for UK and Irish students (“Home Students”) only as funding for international students is very limited.